CClinicalTrials.gg
RecruitingNCT07623902Updated Sep 21, 2026

Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

An interventional study of Gixam System and FIT in CRC Screening and Microbiome, sponsored by Jubaan Ltd.. Recruiting at 8 sites in United States. Open to participants aged 45 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Jubaan Ltd. · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started May 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,436
Allocation
Not applicable
Ages
45 Years to 84 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged 45-84 that are of average risk to develop colorectal cancer and have received a negative result on a Fecal Immunochemical Test (FIT). The main questions it aims to answer are:

  1. Is the Gixam Device effective in identifying persons with pre-cancer or cancer in the colon and rectum that have received a negative FIT result?
  2. Is the use of the Gixam device safe?

Gixam test result will be compared to the findings of a standard of care screening colonoscopy.

Study participants will:

  1. Undergo the Gixam test
  2. Take a FIT at home and ship to a laboratory.
  3. Undergo a standard of care screening colonoscopy.
02

Conditions studied

  • CRC Screening
  • Microbiome
03

In context

Lead sponsor

Jubaan Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Participants aged ≥45 - ≤84 years.
  2. Able to provide a signed informed consent.
  3. Considered by a physician or healthcare provider as being of 'average risk' for CRC.
  4. Scheduled for a screening colonoscopy at investigation site.

Exclusion criteria

Exclusion Criteria:

  1. Undergoing colonoscopy for investigation of symptoms.
  2. Has undergone colonoscopy within preceding nine (9) years except for a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention.
  3. Positive FIT or Fecal Occult Blood Test (FOBT) result within the preceding eleven (11) months.
  4. Positive Cologuard, Sheild, ColoSense or Epi proColon test within the preceding three (3) years.
  5. History of colorectal cancer.
  6. Family history of colorectal cancer, defined as having one or more first- degree relatives (parent, sibling, or child) with CRC at any age.
  7. Participant has a diagnosis or medical / family history of any of the following conditions, including:

    • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome)
    • Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
    • Other hereditary cancer syndromes including but not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.
  8. Participant has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
  9. Participants with a disability to extend their tongue.
  10. Participants with tongue tremor.
  11. Participants with tongue piercing.
  12. Participants that had a dental visit in the 7 days prior to the Gixam test.
  13. Participants that have taken antibiotics or anti-fungal medications in the 14 days prior to the Gixam test.
  14. Participants that have taken probiotics in the 14 days prior to the Gixam test.
  15. Participant is pregnant.
  16. Participant has any condition that in the opinion of the Investigator should preclude participation in the study.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,436 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    All enrolled participants will undergo the same intervention: Gixam test, FIT, and screening colonoscopy

    Device: Gixam System · Diagnostic Test: FIT · Procedure: Standard of care screening colonoscopy

Interventions

  • DeviceGixam System

    All participant will undergo the Gixam test per device instructions for use

  • Diagnostic testFIT

    FIT kit will be handed out to the study participant, who will later sample stool at home and mail the specimen to a reference laboratory for analysis.

  • ProcedureStandard of care screening colonoscopy

    All participants will undergo a standard of care screening colonoscopy which serves as the gold truth in this study

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint

    Number of device-related adverse events and serious adverse events.

    Time frame: From enrollment to the end of study at 30 days after

  2. Primary Efficacy Endpoints

    Sensitivity and specificity of Gixam in participants with a negative FIT result.

    Time frame: Through study completion, an average of 30 days

Secondary outcomes

  1. Confirmatory Secondary Efficacy Endpoints

    Standalone sensitivity and specificity of Gixam in general average risk population.

    Time frame: Through study completion, an average of 30 days

07

Study locations

7 of 8 sites recruiting
  • East View Medical Research, LLC
    Mobile, Alabama 36606, United States
    Recruiting
  • Gastro Care Institute
    Lancaster, California 93534, United States
    Recruiting
  • Orlando Gastroenterology, PA
    Orlando, Florida 32835, United States
    Recruiting
  • Comprehensive Gastrointestinal Health, LLC
    Northbrook, Illinois 60062, United States
    Active, not recruiting
  • Westchester Putnam Gastro
    Carmel, New York 10549, United States
    Recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
  • Great Lakes Gastroenterology Research, LLC
    Mentor, Ohio 44060, United States
    Recruiting
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623902
Lead sponsor
Jubaan Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
May 18, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion